{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:11:40Z","timestamp":1791583900909,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T00:00:00Z","timestamp":1274745600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s00277-010-0991-4","type":"journal-article","created":{"date-parts":[[2010,5,24]],"date-time":"2010-05-24T09:53:33Z","timestamp":1274694813000},"page":"1099-1105","source":"Crossref","is-referenced-by-count":24,"title":["Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib"],"prefix":"10.1007","volume":"89","author":[{"given":"Baijun","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Chunhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,25]]},"reference":[{"key":"991_CR1","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","volume":"86","author":"S Sacchi","year":"1999","unstructured":"Sacchi S, Kantarjian HM, O'Brien S et al (1999) Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86:2632\u20132641","journal-title":"Cancer"},{"key":"991_CR2","first-page":"513","volume":"91","author":"A Gratwohl","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J et al (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91:513\u2013521","journal-title":"Haematologica"},{"key":"991_CR3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038\u20131042","journal-title":"N Engl J Med"},{"key":"991_CR4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S et al (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276\u2013283","journal-title":"Blood"},{"key":"991_CR5","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"S Soverini","year":"2005","unstructured":"Soverini S, Martinelli G, Rosti G et al (2005) ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and horter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 23:4100\u20134109","journal-title":"J Clin Oncol"},{"key":"991_CR6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.22398","volume":"109","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Garcia-Manero G et al (2007) Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109:248\u2013255","journal-title":"Cancer"},{"key":"991_CR7","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/cncr.20975","volume":"103","author":"D Marin","year":"2005","unstructured":"Marin D, Kaeda JS, Andreasson C et al (2005) Phase I\/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 103:1850\u201318555","journal-title":"Cancer"},{"key":"991_CR8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, J\u00f8rgensen HG, Allan E et al (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319\u2013325","journal-title":"Blood"},{"key":"991_CR9","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/1078-0432.CCR-05-0429","volume":"12","author":"HG J\u00f8rgensen","year":"2006","unstructured":"J\u00f8rgensen HG, Copland M, Allan EK et al (2006) Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 12:626\u2013633","journal-title":"Clin Cancer Res"},{"key":"991_CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.20903","volume":"83","author":"WG Zhang","year":"2008","unstructured":"Zhang WG, Wang FX, Chen YX et al (2008) Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol 83:185\u2013188","journal-title":"Am J Hematol"},{"key":"991_CR11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/cncr.22535","volume":"109","author":"S Fruehauf","year":"2007","unstructured":"Fruehauf S, Topaly J, Buss EC et al (2007) Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 109:1543\u20131549","journal-title":"Cancer"},{"key":"991_CR12","first-page":"1783","volume":"9","author":"MC Bene","year":"1995","unstructured":"Bene MC, Castoldi G, Knapp W et al (1995) Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9:1783\u20131786","journal-title":"Leukemia"},{"key":"991_CR13","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","volume":"113","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Kantarjian HM, Jones D (2009) Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113:2154\u20132160","journal-title":"Blood"},{"key":"991_CR14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B et al (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117\u2013223","journal-title":"Cancer Cell"},{"key":"991_CR15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","volume":"101","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, Talpaz M, O'Brien S et al (2003) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101:473\u2013475","journal-title":"Blood"},{"key":"991_CR16","first-page":"2092","volume":"9","author":"JA Zonder","year":"2002","unstructured":"Zonder JA, Pemberton P, Brandt H, Mohamad AN, Schiffer CA (2002) The effect of dose increase to imatinib mesylate in patients with chronic or accelerated phase chronic myeloid leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 9:2092\u20132097","journal-title":"Clin Cancer Res"},{"key":"991_CR17","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","volume":"102","author":"D Marin","year":"2003","unstructured":"Marin D, Goldman JM, Olavarria E, Apperley J (2003) Transient benefit only from increasing the imatinib dose in CML patients who do not acheive cytogenetic remissions on conventional doses. Blood 102:2702\u20132703","journal-title":"Blood"},{"key":"991_CR18","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","volume":"86","author":"S O'Brien","year":"1995","unstructured":"O'Brien S, Kantarjian H, Keating M (1995) Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86:3322\u20133326","journal-title":"Blood"},{"key":"991_CR19","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/cncr.10436","volume":"94","author":"S O'Brien","year":"2002","unstructured":"O'Brien S, Talpaz M, Cortes J et al (2002) Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 94:2024\u20132032","journal-title":"Cancer"},{"key":"991_CR20","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/sj.leu.2402775","volume":"16","author":"AJ Tipping","year":"2002","unstructured":"Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV (2002) Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 16:2349\u20132357","journal-title":"Leukemia"},{"key":"991_CR21","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1002\/cncr.10543","volume":"94","author":"B Scappini","year":"2002","unstructured":"Scappini B, Onida F, Kantarjian HM et al (2002) In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 94:2653\u20132662","journal-title":"Cancer"},{"key":"991_CR22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004","journal-title":"N Engl J Med"},{"key":"991_CR23","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","volume":"101","author":"R Bhatia","year":"2003","unstructured":"Bhatia R, Holtz M, Niu N et al (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101:4701\u20134707","journal-title":"Blood"},{"key":"991_CR24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"991_CR25","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","volume":"99","author":"MS Holtz","year":"2002","unstructured":"Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R (2002) Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99:3792\u20133800","journal-title":"Blood"},{"issue":"Suppl 1","key":"991_CR26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.leukres.2003.10.017","volume":"28","author":"MJ Mauro","year":"2004","unstructured":"Mauro MJ, Druker BJ, Maziarz RT (2004) Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28(Suppl 1):71\u201373","journal-title":"Leuk Res"},{"key":"991_CR27","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","volume":"104","author":"J Cortes","year":"2004","unstructured":"Cortes J, O'Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204\u20132205","journal-title":"Blood"},{"key":"991_CR28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.leu.2402917","volume":"17","author":"CH Hui","year":"2003","unstructured":"Hui CH, Goh KY, White D et al (2003) Successful peripheral blood stem cell mobilization with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 17:821\u2013828","journal-title":"Leukemia"},{"key":"991_CR29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2141.2003.04599.x","volume":"123","author":"MW Drummond","year":"2003","unstructured":"Drummond MW, Marin D, Clark RE et al (2003) Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol 123:479\u2013483","journal-title":"Br J Haematol"},{"key":"991_CR30","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/sj.leu.2402996","volume":"17","author":"D Marin","year":"2003","unstructured":"Marin D, Marktel S, Bua M et al (2003) Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon \u03b1. Leukemia 17:1448\u20131453","journal-title":"Leukemia"},{"key":"991_CR31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.11863","volume":"100","author":"TB Sneed","year":"2004","unstructured":"Sneed TB, Kantarjian HM, Talpaz M et al (2004) The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 100:116\u2013121","journal-title":"Cancer"},{"key":"991_CR32","first-page":"227","volume":"88","author":"D Marin","year":"2003","unstructured":"Marin D, Marktel S, Foot N, Bua M, Goldman JM, Apperley JF (2003) Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 88:227\u2013279","journal-title":"Haematologica"},{"key":"991_CR33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.leu.2402869","volume":"17","author":"D Heim","year":"2003","unstructured":"Heim D, Ebn\u00f6ther M, Meyer-Monard S et al (2003) G-CSF for imatinib-induced neutropenia. Leukemia 17:805\u2013807","journal-title":"Leukemia"},{"key":"991_CR34","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/cncr.20285","volume":"100","author":"A Quintas-Cardama","year":"2004","unstructured":"Quintas-Cardama A, Kantarjian H, O'Brien S et al (2004) Granulocyte colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 100:2592\u20132597","journal-title":"Cancer"},{"key":"991_CR35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.20742","volume":"103","author":"HG Jorgensen","year":"2005","unstructured":"Jorgensen HG, Copland M, Holyoake TL (2005) Granulocyte colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer 103:210\u2013211","journal-title":"Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-0991-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-010-0991-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-0991-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T23:57:46Z","timestamp":1591315066000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-010-0991-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,25]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1007\/s00277-010-0991-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,25]]}}}